Zenara Pharma, a Biophore subsidiary, gets DCGI nod for favipiravir tablets 

The company informed that these tablets, to be marketed under brand name Favizen, will be manufactured with in-house API

Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has announced that it has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19. The tablet, which will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.

Dr Jagadeesh Babu Rangisetty, Co-founder and MD, says, “In the ongoing pandemic, it has become extremely critical for pharma companies to quickly provide safe and effective treatment options for patients with COVID-19.  I am proud to say that we have our own in-house API and are not dependent on any imports for the production. We are also in talks with various institutions to make the tablets available at discounted or no cost to underprivileged patients.”

The company, through a statement, informed that it is in talks with multiple state institutions and several hospitals in India to ensure that Favizen is readily available for patients in need. The company is also likely to tie up with other partners across the country to increase patient coverage. Internationally, Zenara has the manufacturing and distribution capabilities to improve access to this treatment around the world and has already begun exports to the Middle East and Latin American countries.

Biophore PharmaceuticalsCovid-19 treatmentDCGI approvalFavipiravirFavizenZenara Pharma
Comments (0)
Add Comment